Aileron Therapeutics, Inc. (ALRN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALRN Stock Price Chart Interactive Chart >
ALRN Price/Volume Stats
|Current price||$2.60||52-week high||$15.00|
|Prev. close||$2.58||52-week low||$1.79|
|Day high||$2.80||Avg. volume||30,800|
|50-day MA||$2.68||Dividend yield||N/A|
|200-day MA||$4.74||Market Cap||11.81M|
Aileron Therapeutics, Inc. (ALRN) Company Bio
Aileron Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of therapeutics called stapled peptides, which represent the first general solution, or "scaffold" for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. The company's lead product candidate ALRN-6924 is being evaluated in multiple clinical trials. The company was founded in 2005 and is based in Cambridge, Massachusetts.
Most Popular Stories View All
ALRN Latest News Stream
|Loading, please wait...|
ALRN Latest Social Stream
View Full ALRN Social Stream
Latest ALRN News From Around the Web
Below are the latest news stories about AILERON THERAPEUTICS INC that investors may wish to consider to help them evaluate ALRN as an investment opportunity.
Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The Nasdaq Stock Market noting that Aileron has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the company to maintain a minimum closing bid price of $1.00 p
Aileron Therapeutics, Inc. (ALRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will become effective at 5:00 p.m. ET today. Aileron’s common stock will continue to be traded on the
Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ALRN Price Returns